CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $34.5 million for the quarter, compared to a net loss of $16.9 million for the same period in 2024. The increase in net loss was primarily due to higher personnel-related expenses, including compensation costs from increased headcount, as well as elevated professional and consultant fees and marketing-related costs. The company's cash position, including cash equivalents and marketable securities, was $688.4 million as of March 31, 2025, down from $742.0 million as of December 31, 2024. CG Oncology continues to focus on developing and commercializing therapies for bladder cancer, with significant progress in its clinical programs. Key business updates include the presentation of updated BOND-003 clinical results at the American Urological Association $(AUA.AU)$ meeting, showing promising durability and tolerability data. The company anticipates initiating the Biologics License Application $(BLA.AU)$ submission for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer (NMIBC) in the second half of 2025. Furthermore, the enrollment for the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC is expected to be completed in the latter half of 2025.